Related content

Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer

By Oorschot B.   Assenbrunner B.   Schuler M.   Beckmann G.   Flentje M.  

Strahlentherapie und Onkologie, Vol. 190, Iss. 3, 2014-03 ,pp. : 270-275

Springer Publishing Company

Access to resources Recommend Favorite

A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer: Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor

By Ostheimer C.   Bache M.   Güttler A.   Kotzsch M.   Vordermark D.  

Strahlentherapie und Onkologie, Vol. 190, Iss. 3, 2014-03 ,pp. : 276-282

Springer Publishing Company

Access to resources Recommend Favorite

Definition of stereotactic body radiotherapy: Principles and practice for the treatment of stage I non-small cell lung cancer

By Guckenberger M.   Andratschke N.   Alheit H.   Holy R.   Moustakis C.   Nestle U.   Sauer O.  

Strahlentherapie und Onkologie, Vol. 190, Iss. 1, 2014-01 ,pp. : 26-33

Springer Publishing Company

Access to resources Recommend Favorite

Lung pathology: The molecular genetics of non-small cell lung cancer

By Fong Kwun   Zimmerman Paul   Smith Peter  

Pathology, Vol. 27, Iss. 4, 1995-10 ,pp. : 295-301

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Early reduction in tumour [¹⁸F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone

By Trigonis Ioannis   Koh Pek   Taylor Ben   Tamal Mahbubunnabi   Ryder David   Earl Mark   Anton-Rodriguez Jose   Haslett Kate   Young Helen   Faivre-Finn Corinne   Blackhall Fiona   Jackson Alan   Asselin Marie-Claude  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Iss. 4, 2014-04 ,pp. : 682-693

Springer Publishing Company

Access to resources Recommend Favorite